

Global Small-Mid Cap Equity Strategy Notes Second Quarter 2024 (1 April – 30 June 2024)

The Brandes Global Small-Mid Cap Equity Strategy rose 0.39% (gross of fees), outperforming its benchmark, the MSCI ACWI SMID Cap Index, which declined 2.06%.

Positive Contributors

Notable performers included holdings in financials, led by Spanish insurer Linea Directa Aseguradora, Slovenian bank Nova Ljubljanska Banka, and U.K.-based St. James's Place.

Select health care investments also helped returns, specifically Dutch multinational conglomerate Koninklijke Philips and U.S.-based biotech firm United Therapeutics. Philips reached a settlement related to its ventilators, removing significant uncertainty about its legal liabilities.

Outside of financials and health care, standout contributors included Hungary's Magyar Telekom, Chinese textile firm Yue Yuen Industrial, Taiwan-based Asustek Computer, and U.K.-based aerospace and defense firm Rolls-Royce. Rolls-Royce continued to benefit from the ongoing recovery in its end-markets, and the market reacted favorably to the firm's announcement that it would leave its 2024 guidance unchanged.

Performance Detractors

Mexico was among the worst-performing markets in the benchmark, as presidential election results prompted investor concern about the prospects for less market-friendly policies from the new government. Our holdings there, namely real estate investment trust Fibra Uno and cement manufacturer Cemex, were impacted by the negative market sentiment. Nonetheless, we continue to have confidence in the fundamentals of these holdings and maintain our positions.

Utilities represented the best-performing component of the benchmark as the sector has become a secondary beneficiary of the growing demand for AI, which will likely result in rising electricity usage. As such, our lack of exposure to the sector hurt relative returns.

Other detractors included French consumer products manufacturer Societe BIC, U.S. health care services provider Pediatrix Medical Group, Greece-based Piraeus Financial Holdings, and newly added U.K. luxury goods firm Burberry.

Select Activity in the Quarter

Taro Pharmaceutical, a long-term holding in the portfolio, was acquired by Sun Pharmaceutical during the quarter. Another long-held position, National Western Life Insurance, is in the process of being acquired as well. The common threads for both investments included: 1) poor corporate governance with a controlling shareholder; 2) underperforming businesses; and 3) periods of what we believed were rock-bottom market valuations.

Taro is an Israeli generic pharmaceutical company controlled by India-based Sun Pharmaceutical. We first added Taro to our portfolios several years ago as its generics business struggled with increasing competition and lack of new product development. At the time, the company had a large net cash position that accounted for nearly one-third of its market value. During our holding period, Taro's fundamentals continued to deteriorate, and the value of its financial assets became an ever-greater percentage of its market value. At its nadir in 2023, Taro's market cap was lower than its net-cash position while the business continued to maintain positive free cash flow. Despite the company's struggles over this long holding period, we continued to believe it could turn around as its pipeline of new generic drugs was slowly strengthening. As it happens, we were not alone in being optimistic about Taro's prospects.

In May 2023, Taro's controlling shareholder, Sun Pharmaceutical, made an offer to buy out minority shareholders for \$38 a share. After this initial valuation was rejected, Sun and Taro directors ultimately agreed on a price of \$43 in January 2024. This price still fell far below our estimate of Taro's intrinsic value, and we thus voted *against* the transaction. Unfortunately, the proxy voting services recommended to vote *for* the transaction, resulting in Brandes along with a few activist investors losing out in what was likely a close vote.

National Western Life Insurance (NWLI) was a family-controlled life insurance company with a conservative balance sheet and uninspiring investment returns. In exchange for investing in a business led and controlled by the fourth generation of the Moody family, shareholders received a small dividend and a claim on the company's tangible book value. At the stock's low point, NWLI traded at less than one-third of its book value. The timing for realizing the full value of the underlying business was uncertain, but the low market value incentivized us to have prolonged patience. The investment case centered on the depressed market valuation, with an anemic 4% to 6% annual book value growth partially offsetting the cost of waiting.

Finally, in May 2023, NWLI announced it was exploring strategic alternatives and had hired a financial advisor. In October 2023, the company announced it had agreed to be acquired for \$500 a share, or 90% of its book value. Unlike the case for Taro, we viewed the offer price for NWLI as fair. The transaction is expected to close in early July 2024.

We initiated a position in U.K.-based luxury goods company Burberry.

Over the past few years, the luxury goods industry has underperformed the broader global market (MSCI ACWI SMID Cap). Concerns about the economic prospects of Asia have weighed on investor sentiment for many companies in the industry, including Burberry.

Burberry primarily sells apparel and accessories, and has a rich history, having been founded in 1856. The company was publicly listed for a second time in 2002 after being part of U.K. retail conglomerate Gus for almost five decades. Since it became public again, Burberry has been evolving its business model, with a focus on elevating the brand.

When Gus spun out Burberry, more than half of its revenue came from the wholesale channel. After investing in its retail channel roll-out, almost 80% of the company's revenue is now from direct-to-consumer sales, either through its stores or online—a level closer to Burberry's luxury peers. This development was a positive move for the company as shifting away from the wholesale channel toward a direct retail model helps a luxury brand better control its brand image (customer experience and pricing). Additionally, Burberry has eliminated non-core product categories, focusing on those for which it has a distinct legacy and brand appeal. While Burberry's management team turned over in 2022, the core strategy has remained largely unchanged.

Asia Pacific accounts for more than 40% of Burberry's revenue, with China accounting for about half of that amount. This is typical for players in the industry as Asia Pacific represents the largest luxury goods market in the world. Recently, a weak yen and a sputtering economy in China have made for a lackluster luxury goods marketplace. However, while the luxury market is sensitive to changes in the economic environment, a long history suggests the top luxury brands can accrue value even with little country-level economic growth. For instance, it is estimated that the luxury goods market in Japan has continued to grow over the past 15 years even as the Japanese economy contracted (in U.S. dollar terms), a phenomenon that we do not think can be solely explained by increasing tourist flows into the country.

With what we consider compelling market valuations, Burberry joins Swatch in our client portfolios as we patiently wait for evidence that the luxury brand players can endure.

Year-to-Date Briefing

The Brandes Global Small-Mid Cap Equity Strategy rose 8.56%, outperforming its benchmark, the MSCI ACWI SMID Cap Index, which increased 2.83% in the six months ended 30 June 2024.

Holdings in financials (e.g., Nova Ljubljanska Banka, AIB Group, Linea Directa Aseguradora, Banco Latinoamericano) and industrials (e.g., Embraer, Rolls-Royce) drove performance. Several communication services holdings also delivered robust results, particularly Magyar Telekom and media firms ITV and Atresmedia.

Other notable performers included health care holdings Organon & Co, Phibro Animal Health, and United Therapeutics, as well as construction materials company Buzzi. Additionally, as was the case for the quarter, Yue Yuen was a strong contributor to returns.

Major detractors included biotech firm Grifols, luxury goods companies Swatch and Kering, as well as holdings in commercial services and supplies, namely Societe BIC and S-1 Corporation.

Grifols declined mainly in the first quarter following a short seller's report that questioned the company's debt and corporate governance practices. We continue to believe there is a potentially meaningful upside to Grifols. The company recently completed the sale of an ownership stake in Shanghai RAAS, which should help it improve its financial leverage in the near term.

Furthermore, similar to the quarter, allocation to Mexico weighed on returns.

Current Positioning

The strategy continues to hold key overweight positions in consumer staples, health care, communication services, and financials, while maintaining underweights to utilities and typically cyclical sectors such as consumer discretionary and industrials.

Geographically, we continue to find value opportunities outside the United States, especially in the United Kingdom, Japan, and emerging markets. We remain materially underweight to the United States, with our allocation less than half the benchmark's 52% weighting.

Global small-mid cap equities continue to represent, in our opinion, fertile ground for fundamentally solid businesses trading at a discount to their estimated intrinsic values. Within the asset class, value stocks (MSCI ACWI SMID Cap Value) continue to trade in the highest decile of discount levels to the broader market (MSCI ACWI SMID Cap) on a variety of valuation metrics, including forward price/earnings, price/cash flows, and enterprise value/sales.

We believe that paying extremely close attention to valuations enables us to choose opportunities that others may miss. We are enthusiastic about the potentially undervalued companies we are finding, and the diversification offered by the Brandes Global Small-Mid Cap Equity Strategy.

Term definitions: <https://www.brandes.com/termdefinitions>

The MSCI ACWI SMID Cap Index with net dividends captures mid and small cap representation across developed and emerging market countries.

The MSCI ACWI SMID Cap Value Index captures mid and small cap securities across developed and emerging markets countries exhibiting overall value style characteristics, defined using book value to price, 12-month forward earnings to price, and dividend yield.

MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products.

Diversification does not assure a profit or protect against a loss in a declining market.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. International and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Unlike bonds issued or guaranteed by the U.S. government or its agencies, stocks and other bonds are not backed by the full faith and credit of the United States. Stock and bond prices will experience market fluctuations. Please note that the value of government securities and bonds in general have an inverse relationship to interest rates. Bonds carry the risk of default, or the risk that an issuer will be unable to make income or principal payment. There is no assurance that private guarantors or insurers will meet their obligations. The credit quality of the investments in the portfolio is not a guarantee of the safety or stability of the portfolio. Investments in Asset Backed and Mortgage Backed Securities include additional risks that investors should be aware of such as credit risk, prepayment risk, possible illiquidity and default, as well as increased susceptibility to adverse economic developments. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a guarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

Ireland/Europe: FOR PROFESSIONAL INVESTOR USE ONLY. Issued by Brandes Investment Partners (Europe) Limited (Brandes Europe), Alexandra House, The Sweepstakes, Ballsbridge, Dublin, D04 C7H2, Ireland. Registered in Ireland Number 510203. Authorised and regulated by the Central Bank of Ireland. This report is being provided for information purposes only, no representation or warranty is made, whether express or implied as to the accuracy or completeness of the information provided. To the fullest extent permitted by law Brandes Europe shall not be liable for any loss or damage suffered by any person as a result of the receipt of this report. Recipients of this report should obtain their own professional advice. The distribution of this report may be restricted by law. No action has been or will be taken by Brandes Europe to permit the possession or distribution of this report in any jurisdiction where action for that purpose may be required. Accordingly, this report may not be used in any jurisdiction except under circumstances that will result in compliance with any applicable laws and regulations. Persons to whom this

report is communicated should inform themselves about and observe any such restrictions. This information is being issued only to, and/or is directed only at (i) persons who have professional experience in matters relating to investments or (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or to whom it may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This report is a confidential communication to, and solely for the use of, the persons to whom it is distributed to by Brandes Europe.